Laurus Labs Q2 Profit Surges 126% to ₹442 Crore, Beats Estimates: Board Declares Interim Dividend
_1945561460.jpg)
Hyderabad-headquartered pharmaceutical major Laurus Labs delivered an exceptional set of financial numbers for the second quarter of the 2026–27 fiscal year, outperforming Street expectations across top-line, operating profit, and net earnings. Propelled by sustained traction in its Contract Development and Manufacturing Organization (CDMO) vertical and resilient demand in the generic formulations space, the company's consolidated net profit skyrocketed by over 126 percent year-on-year to reach ₹442 crore, up sharply from ₹195 crore reported in the corresponding quarter of the previous fiscal. The performance comfortably surpassed CNBC-TV18 consensus estimates of ₹354.1 crore. Buoyed by the strong operational performance released ahead of market hours, investor sentiment remained robust on Thursday, driving the stock nearly 3 percent higher by the closing bell.
Key Financial Highlights: EBITDA Expands 86% as Operating Margins Widen to 34%
The drug manufacturer registered double-digit revenue expansion alongside marked margin expansion across its active manufacturing lines:
Top-Line Growth: Consolidated revenue from operations for the July-September quarter climbed 33.4 percent year-on-year to ₹2,206 crore, compared to ₹1,653.5 crore in Q2 of the previous fiscal, topping analyst forecasts of ₹2,109.5 crore.
Operating EBITDA Surge: Earnings before interest, taxes, depreciation, and amortization (EBITDA) surged 86 percent year-on-year to ₹750 crore from ₹403.3 crore, comfortably beating the market benchmark of ₹644.4 crore.
Margin Expansion: Operating EBITDA margin expanded significantly by 960 basis points to settle at 34 percent against 24.4 percent in the year-ago period, outstripping the consensus projection of 30.5 percent.
Shareholder Payout: Board Approves Interim Dividend of ₹1 Per Equity Share
Rewarding shareholders following the strong quarterly earnings run, the company's board of directors greenlit a direct cash dividend distribution:
Dividend Announcement: Meeting on Thursday, October 29, 2026, the Board of Directors approved an interim dividend of ₹1 per fully paid equity share of face value ₹2 each, representing a 50 percent payout on face value.
Key Record Date: The company has formally fixed Friday, November 6, 2026, as the record date for determining eligible shareholders entitled to receive the dividend payout.
Disbursement Timeline: Laurus Labs stated that the interim dividend will be credited or dispatched to investors on or after November 19, 2026.
Strategic Drivers: CDMO Scalability and Investments in Oligonucleotides & Peptides
Operational gains were underpinned by expanding manufacturing volumes and investments in high-value biopharmaceutical technologies:
CDMO and Affordable Medicine Momentum: Strong commercial deliveries for international clients bolstered the CDMO segment, complemented by steady supply agreements across the company's core generic drug offerings.
New Technology Inroads: To reinforce long-term contract manufacturing capabilities, Laurus Labs announced strategic capital investments in two specialized technology verticals: oligonucleotides and peptide resins, aimed at catering to next-generation therapeutic pipelines.
Focused Research Spending: The company allocated ₹65 crore toward research and development (R&D) activities during the second quarter, accounting for 2.9 percent of total operating revenues, a 6 percent moderation compared to the previous year.
_939329610_351x234.jpg)
_450284982_351x234.jpg)
_1652337411_351x234.jpg)
_1713946510_351x234.jpg)
_1807190829_351x234.jpg)